ClinicalTrials.gg
WithdrawnNCT05970263IKANOSUpdated Feb 1, 2024

IKANOS: Breztri Maintenance Versus Any Non-Triple Inhaled Therapy After Hospitalization for a COPD Exacerbation in the US

A Phase 4 interventional study of Budesonide/glycopyrrolate/formoterol fumarate (Breztri Aerosphere) 320 μg/18 μg/9.6 μg administered as two inhalations, twice daily. and External Comparator in COPD, sponsored by AstraZeneca. Withdrawn. Open to participants aged 40 Years to 100 Years. Per ClinicalTrials.gov, last updated 2024-02-01.

Sponsored by AstraZeneca · Phase 4, Interventional, and Treatment

Why this study was withdrawn
Recruitment challenges

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
40 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca — 14 open to participants now, 15 under way, 4 of them phase 3. Pulmonary Disease, Chronic Obstructive · AstraZeneca.

Enrollment
191st of 194
0 · median 137
Started
2024
with 16 others
Phase 4
19 of 284
2 open now
Registered
248th of 284
by date

Among the 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca, this one is the 191st largest by enrollment of the 194 interventional ones that give a count, is one of 17 that started in 2024, is one of 19 in phase 4, and was the 248th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 857 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

14 of the 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 14 open studies →

Who these studies take

Of the 557 Pulmonary Disease, Chronic Obstructive studies recruiting now, 306 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 89 take healthy volunteers.

This study: 40 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca, or all of them as a file.
02

Study summary

This study will evaluate whether prompt initiation and maintenance of Breztri (a triple therapy) following a severe COPD exacerbation hospitalization, is associated with a lower risk of all-cause readmissions at 90 days post-discharge, compared to receiving any non-triple inhaled therapy.

Read the detailed description

IKANOS is a prospective, open-label, minimally interventional Hybrid Study in the US Comparing Initiation of Breztri Maintenance versus Any Non-Triple Inhaled Therapy at Discharge after a Hospitalization for a COPD Exacerbation.

The interventional arm will be comprised of around 1000 patients for whom Breztri maintenance is prescribed, and the first dose is received prior to hospital discharge (the "index discharge") after a severe COPD exacerbation (the index admission).

At the end of the recruitment period of the interventional arm, the external comparator arm will be constructed from real-world data of patients contemporaneous with those in the interventional arm, from the same or similar integrated delivery network as the interventional arm and who are similar in key clinical and demographic characteristics.

Patients will be followed-up through their data and call center contact for up to 12 months.

03

Conditions studied

  • COPD

Keywords

  • COPD;
  • readmissions;
  • maintenance therapy;
  • triple therapy;
  • real-world evidence;
  • hospital discharge;
  • mortality;
  • cardiopulmonary events,
  • exacerbations
04

Who can participate

Ages eligible
40 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Patients are included into the study if they meet the following criteria :

  1. Adults aged 40 years and above as of the index hospitalization admission date (for the intervention arm only).
  2. Primary or secondary diagnosis of as documented in the database on or before admission.
  3. Hospital admission for a COPD exacerbation (primary or secondary cause) (ie, the index admission).
  4. Availability of at least 6 months of data in the PHD-LRx-Dx database prior to the index admission (for the comparator arm only).
  5. Additional inclusion criteria for the interventional arm:

    1. Willingness to use Breztri as an inhaled maintenance medication as prescribed by their physician.
    2. Willingness and ability to sign during index admission and before discharge.
    3. Availability of home-based access to telephone calls.
    4. Availability of home-based access to the internet for PRO measurement and inhaler training materials.
    5. Willingness to be contacted by a qualified medical professional for safety monitoring.
    6. Willingness and ability to participate, on their own or through the assistance of their caregivers, in remote, online patient-reported outcome measurement at designated intervals
    7. Physician decision that patient is eligible for treatment with Breztri according to the approved USPI.
    8. Any females of must be using a form of highly effective methods of and have a negative urine pregnancy test result
  6. Additional inclusion criterion for the comparator arm:

    1. Received non-triple inhaled therapy for COPD within 30 days prior to discharge or up to 30 days post-discharge, including:

      • ICS/LABA.
      • LABA/LAMA.
      • ICS.
      • LABA.
      • LAMA.
      • SABA/SAMA.
      • SABA.
      • SAMA.
      • Other inhaled COPD therapy not classified as triple therapy.

Exclusion Criteria:

Patients are excluded from the study if they meet any of the following criteria:

  1. Having received triple inhaled maintenance therapy (fixed-dose, or open) for COPD or other indications 6 months prior to index admission.
  2. Any documented use of respiratory biologics 6 months prior to index admission.
  3. Patients on palliative care, including hospice.
  4. Discharge to institutional care other than a rehabilitation facility (eg, other hospital, or similar). Patients discharged to rehabilitation facility are eligible to participate. Note: Because patients are enrolled in the intervention arm prior to discharge, this criterion should be assessed using the working knowledge of the treating physician at the time of patient enrollment.
  5. Mortality on or before index discharge.
  6. Conditions including lung surgery (excluding thoracentesis or chest tube insertion or thoracostomy) in 6 months prior to index admission, history of pulmonary lobectomy, cystic fibrosis, interstitial lung disease, lung cancer, or alpha-1 antitrypsin deficiency (A1ATD) inducing severe disease as recorded in the PHD-LRx-Dx database.
  7. For females only - currently pregnant (confirmed with positive pregnancy test) or breast-feeding or planning to become pregnant in the year following index discharge.
  8. Additional exclusion criteria for the interventional arm:

    1. Discharged on a triple inhaled maintenance therapy in addition to Breztri.
    2. Patients who have a history of to β2-agonists, budesonide or any other components, glycopyrronium or other muscarinicanticholinergics, or any component of the MDI.
    3. Patients who are clinically unstable, ie, still admitted within the intensive care unit,with ongoing dyspnea, requiring vasopressors or round-the-clock positive airway pressure ventilatory support.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Breztri

    1. Interventional Arm: patients receive : 1. First dose of Breztri during hospitalization and discharge with 7-day Breztri inhaler 2. Breztri refills to cover 12-month follow-up period, mailed in 90-day supply from a central pharmacy. Emergency resupply is also available if needed.

    Drug: Budesonide/glycopyrrolate/formoterol fumarate (Breztri Aerosphere) 320 μg/18 μg/9.6 μg administered as two inhalations, twice daily.

  • Other
    External Comparator - Non-Triple

    2. External Comparator Arm: patient who receive any non-triple inhaled therapy following a hospitalization for severe COPD exacerbation. This arm will be constructed of de-Identified patient.

    Other: External Comparator

Interventions

  • DrugBudesonide/glycopyrrolate/formoterol fumarate (Breztri Aerosphere) 320 μg/18 μg/9.6 μg administered as two inhalations, twice daily.

    2 inhalations twice daily administered by oral inhalation, from a metered dose inhaler, over a 12-month follow-up period.

  • OtherExternal Comparator

    Received any inhaled therapy, excluding triple inhaled maintenance therapy, during index hospitalization and refilled within 30 days before or after discharge from index hospitalization

06

What researchers measure

Primary outcomes

  1. Proportion of patients with an all-cause readmission

    Time frame: 90 days post-index discharge

Secondary outcomes

  1. Number of all-cause readmissions

    Time frame: 90 days post-index discharge

  2. Time to first all-cause readmission

    Time frame: 1 year post-index discharge

  3. Proportion of patients with all-cause readmissions

    Time frame: 30 days and 1 year post-index discharge

  4. number of all-cause readmissions per time period

    Time frame: 30 days and 1 year post-index discharge

  5. proportion of patients experiencing COPD moderate/severe exacerbations

    Time frame: 30 days, 90 days and 1 year post-index discharge

  6. proportion of patients experiencing COPD severe exacerbations

    Time frame: 30 days, 90 days, and 1 year post-index discharge

  7. number of COPD moderate/severe exacerbations per time period

    Time frame: 30 days, 90 days, and 1 year post-index discharge

  8. number of COPD severe exacerbations per time period

    Time frame: 30 days, 90 days, and 1 year post-index discharge

  9. time to first COPD moderate/severe exacerbations

    Time frame: 1 year post-index discharge

  10. time to first COPD severe exacerbations

    Time frame: 1 year post-index discharge

  11. proportion of patients experiencing all-cause mortality

    Time frame: 90 days and 1 year post-index discharge

  12. time to all-cause mortality

    Time frame: 1 year post-index discharge

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at

Data sharing details ↗ · astrazenecagrouptrials.pharmacm.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jan 2024; primary completion for Dec 2025, 23 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 27, 2023
First posted
Aug 1, 2023
StartEst.
Jan 19, 2024
Primary completionEst.
Dec 31, 2025
CompletionEst.
Dec 31, 2025
Last update
Feb 1, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05970263
Lead sponsor
AstraZeneca
Collaborators
Iqvia Pty Ltd, Premier Inc
Responsible party
Sponsor
First posted
Aug 1, 2023
Start date
Jan 19, 2024 (estimated)
Primary completion
Dec 31, 2025 (estimated)
Completion
Dec 31, 2025 (estimated)
Last update
Feb 1, 2024

Study contacts

Igor Barjaktarevic, MD, PhD
principal investigator · David Geffen School of Medicine

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion